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Abstract
Introduction: Loss of residual renal function (RRF) as well as 
high peritoneal glucose exposure are associated with in-
creased peritonitis frequency in peritoneal dialysis (PD) pa-
tients. Our objective was to investigate the contribution of 
RRF and peritoneal glucose exposure to peritonitis in PD pa-
tients. Methods: In this prospective longitudinal cohort 
study, 105 incident end-stage renal disease patients that 
started PD between January 2006 and 2015 were studied. 
Follow-up was 5 years with censoring at death or switch to 
another treatment modality. Cox regression models were 
used to calculate the association between glucose exposure, 
RRF, and peritonitis. Kaplan-Meier analysis was used to ex-
amine the difference in occurrence of peritonitis between 
patients with high and low glucose exposure and between 
those with and without residual diuresis. Results: One hun-
dred and five patients were followed for a mean of 23 
months. Fifty-one patients developed a peritonitis. Cox re-
gression models at 6 months showed that glucose exposure 
and not residual diuresis significantly predicted PD peritoni-
tis. Kaplan-Meier analysis after 6 months of follow-up showed 
that time to first PD peritonitis was significantly longer in the 
low glucose exposure group. Similarly, patients with RRF had 
a significantly longer interval to first peritonitis compared to 
patients without RRF. Conclusion: A higher exposure to glu-
cose rather than loss of RRF is associated with an increased 
risk of peritonitis. This confirms the detrimental effects of 
glycemic harm to the peritoneal host defense on invading 
microorganisms and argues for the use of the lowest PD glu-
cose concentrations possible. © 2020 The Author(s) 
Published by S. Karger AG, Basel
Introduction
Worldwide, approximately 272,000 patients are treat-
ed with peritoneal dialysis (PD) because of end-stage re-
nal disease [1]. The most common complication of PD 
is peritonitis which is associated with loss of ultrafiltra-
tion, hospitalization, catheter loss, technique failure, 
transfer to hemodialysis (HD), and considerable mortal-
ity [2, 3]. 
The most frequent etiological agents of PD-associated 
peritonitis worldwide are gram-positive cocci such as 
Staphylococcus epidermidis and other coagulase-negative 
Staphylococci and Staphylococcus aureus [4].
This article is licensed under the Creative Commons Attribution-
NonCommercial-NoDerivatives 4.0 International License (CC BY-
NC-ND) (http://www.karger.com/Services/OpenAccessLicense). 
Usage and distribution for commercial purposes as well as any dis-





Previous studies have identified various modifiable 
(malnutrition, the use of immunosuppressive drugs, pa-
tient training) and nonmodifiable risk factors (age, gen-
der, diabetes, residual renal function [RRF]) for perito-
nitis [2, 5]. There is debate on whether high glucose ex-
posure is a risk factor for peritonitis [6]. Long-term 
exposure to dialysis solutions may cause structural 
changes to the peritoneum and have a causative role in 
changes in peritoneal function. Changes in membrane 
function as a consequence of peritonitis are associated 
with recurrent peritoneal infections [6–8]. Studies that 
have specifically investigated the relation between high 
peritoneal glucose exposure and peritonitis frequency 
yield varying results. Some did not find a significant as-
sociation between glucose exposure and peritonitis fre-
quency [9, 10], whereas another study showed a signifi-
cant increase in the incidence of relapsing and recurrent 
peritonitis in patients with a higher glucose exposure 
[11]. 
Several studies have shown the association between a 
decline in residual renal function and an increased risk of 
peritonitis [12–15]. Presently, it is unknown whether this 
is a direct association or whether it is mediated by other 
factors such as a higher glucose exposure. Patients with a 
decrease in RRF and loss of diuresis are almost inevitable 
treated with higher glucose concentrations to achieve suf-
ficient peritoneal ultrafiltration, thus leading to a higher 
glucose exposure to the peritoneum [16]. Thus far, no 
studies investigated the relation between peritonitis fre-
quency and RRF with taking the glucose exposure into 
account. Therefore, the aim of this study was to unravel 




In this longitudinal single-center cohort study with prospec-
tive data collection, all patients who visited our out-patient clinic 
between January 2006 and 2015 were eligible. All adult (≥18 
years) patients that started PD therapy from the Dialysis Center 
Groningen were included (both continuous ambulatory PD and 
automatic PD). Follow-up was 5 years with censoring at death or 
until termination of PD treatment, whichever occurred first. Pa-
tients who had a peritonitis within 6 weeks of starting PD were 
excluded from the study since the possibility that the peritonitis 
was caused by the PD catheter insertion could not be ruled out. 
As measure for RRF, we primarily used the 24-h urine volume, 
since peritoneal glucose exposure is more closely related to vol-
ume homeostasis than to creatinine clearance (CrCl). As a sensi-
tivity analysis, we used the mean of the urea and CrCl instead of 
residual diuresis as measure for RRF.
PD Treatment
The PD solutions prescribed were continuous ambulatory PD/
DPCA 2 (glucose concentration 1.5%), 3 (4.25%), and 4 (2.3%) 
from Fresenius Medical Care (Bad Homburg, Germany). Perito-
nitis was defined in line with the International Society for PD 
guidelines definition as cloudy dialysate with a dialysate white cell 
count of > 100 cells/µL and > 50% polymorphonucleaire leucocytes. 
PD peritonitis was treated according to the most recent version of 
the International Society for PD committee guidelines [17]. 
Causes of discontinuation of PD were categorized as switching 
to HD, renal transplantation, or death. 
Data Collection
All patients that started PD between January 2006 and 2015 
were included. Follow-up was terminated at January 2016. Patient 
characteristics and clinical data including diuresis volumes were 
collected at the start of PD, at 6 weeks after the start of PD and at 
6 months, 1 year and, next, annually for 5 years or until the end of 
PD. Patients with a urine production of > 200 mL/24 h were con-
sidered to have residual diuresis. There was no loss to follow-up. 
For each patient, the glucose exposure was calculated at 6 weeks 
after the start of PD, after 6 months, after 1 year, and next annu-
ally for 5 years or until the end of PD. The total glucose exposure 
in grams per 24 h was calculated as followed: As an example: a pa-
tient with a PD schedule of 2 dwells of 2 L 2.3% glucose and 2 dwells 
of 2 L 1.5% glucose: (2 × 2 × 23 g) + (2 × 2 × 15 g) = 152 g glucose 
exposure over 24 h [6]. We choose not to include icodextrin be-
cause this water-soluble polysaccharide has very different effects 
on the peritoneal membrane compared to glucose. CrCl was cal-
culated using the following formula: CrCl = (urinary creatinine × 
serum creatinine/24-h urine volume)/1.44.
Statistical Analysis
Statistical analysis was performed using SPSS for Windows 
software, version 20.0 (SPSS Inc., Chicago, IL, USA). Normally 
distributed data were expressed as mean ± SD and categorical data 
as number (%). Independent risk factors for peritonitis were as-
sessed in univariate and multivariate Cox’s proportional hazard 
models. In the multivariate model, we adjusted for sex, age, resid-
ual diuresis, daily peritoneal glucose exposure, serum albumin, 
and use of immunosuppressive drugs. p values < 0.05 were consid-
ered significant. For the Kaplan-Meier analyses of glucose expo-
sure, patients were stratified in 2 groups: group 1: glucose exposure 
0–120 g/24 h and group 2: glucose exposure > 120 g/24 h. Further 
Kaplan-Meier analysis was performed after residual diuresis. 
Therefore, patients were divided in 2 groups: group 1 had residual 
diuresis. Group 2 was anuric. Continuous data were used in de 
multivariate models. Comparisons of peritonitis frequency were 
performed using Kaplan-Meier method. 
Results
Patient Characteristics and Clinical Data
As shown in Table 1, the mean age was 52.8 ± 17.4 years 
and 59% were male. About 87% of the patients had re-
sidual diuresis. Failure of a previous renal transplant and 
HD before PD are the main reasons of loss of residual di-
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uresis. Nineteen percent of the patients had previous kid-
ney transplantation and 2% heart transplantation. Twen-
ty-four percent of the patients used immunosuppressive 
drugs (Table 1). Mean follow-up time was 22.9 ± 
20.3 months. A total of 49% of the patients experienced 
at least one peritonitis. Patients were on dialysis for 16.9 ± 
18.6 months at the first episode of peritonitis. The average 
peritoneal glucose exposure at 6 weeks and after 6 months 
was 119.3 ± 36.0 and 141.6 ± 48.2 g/24 h, respectively 
(Table 2). The glucose exposure during follow-up re-
mained fairly stable (at 1 year: 145 ± 49 g/24 h; at 2 years: 
155 ± 61 g/24 h; at 3 years: 152 ± 40 g/24 h; at 4 years: 
173 ± 57 g/24 h; at 5 years: 152 ± 46 g/24 h). After 6 months, 
75% of the patients had residual diuresis. At time of peri-
tonitis, 69% had residual diuresis.
Residual Diuresis, Glucose Exposure, and Peritonitis 
Incidence
Results of univariate Cox regression analyses are listed 
in Table 3. These data show that in univariate analysis, 
the use of immunosuppressive drugs and serum albumin 
(as parameter for nutritional status) significantly pre-
dicted time to first peritonitis (p ≤ 0.001 and p = 0.001 
respectively). Residual diuresis at baseline (p = 0.50) or 
glucose exposure at baseline (p = 0.10) did not signifi-
cantly predict peritonitis. If the analyses was performed 
with the mean of the urea and CrCl instead of residual 
diuresis as measure for RRF similar results were ob-
tained.
However, Cox regression with the same parameters at 
6 months yielded different results. After 6 months of fol-
low-up, both residual diuresis and glucose exposure were 
significant predictors for peritonitis (p = 0.038 and p < 
0.001, respectively).
The multivariate model (Table 3) yielded identical re-
sults. In a multivariate model adjusting for age, sex, re-
sidual diuresis, daily glucose exposure, serum albumin, 
and use of immunosuppressive drugs, the use of immu-
nosuppressive drugs and serum albumin significantly 
predicted peritonitis (p ≤ 0.001 and p = 0.004, respective-
ly). Furthermore, it showed that after 6 months of PD 
treatment, glucose exposure significantly predicted peri-
tonitis (p = 0.024) whereas residual diuresis did not reach 
significance (p = 0.75). 
Both univariate and multivariate analyses showed that 
peritoneal glucose exposure at 1 year after the start of PD 
also predicted peritonitis (hazard ratio [HR] 4.3, 95% CI 
[2.3–8.2], p ≤ 0.001 and HR 4.0, 95% CI [1.72–9.46], p = 
0.001, respectively), whereas residual diuresis was not sig-
nificant. Analysis at 2 years after the start of PD showed 
Table 1. Baseline patient characteristics and clinical data
Characteristic n = 105
Age, years 52.8±17.4




Residual diuresis 91 (87)
CrCl, mL/min 7.5±9.9
Urea – CrCl, mL/min 10.0±6.1
Diabetes 10 (9.5)
Hypertension 99 (94)
Cardiovascular disease 37 (35)
Previous kidney transplantation 20 (19)
Previous heart transplantation 2 (2)
Albumin, g/L 38.6±4.8
Immunosuppressive drugs 25 (24)
Categorical variables are presented as number (percentage); 
continuous variables are presented as mean ± SD.
CrCl, creatinine clearance.
Table 2. Data during follow-up
Parameters n = 105
Follow-up, months 22.9±20.3
Mortality during follow-up 34 (32)
Number of patients developing peritonitis 51 (49)
Peritonitis incidence, number/year 0.07±0.14











Number of patients without residual diuresis at
the time of peritonitis 17 (31)
Number of patients with residual diuresis at
6 months 75 (75)





CrCl at 6 weeks, mL/min 7.5±9.9











Outcome parameters during follow-up. Categorical variables are 
presented as number (percentage); continuous variables are presented 
as mean ± SD.
CrCl, creatinine clearance; PD, peritoneal dialysis; CAPD, conti-





that glucose exposure still predicted peritonitis univari-
ately (HR 1.7, 95% CI [1.0–2.9], p = 0.045), but not mul-
tivariately; in this multivariate analysis at 2 years after the 
start of PD, only the use of immunosuppressive drugs re-
mained significant.
Kaplan-Meier analysis of the peritonitis-free survival 
showed that patients with a high (> 120 g/24 h) daily glu-
cose exposure at 6 weeks and at 6 months had a shorter 
time to peritonitis compared to patients that had a low 
daily glucose exposure (≤120 g/24 h; Fig. 1a, b). 
Kaplan-Meier analysis of the peritonitis-free survival 
of the patient groups categorized by the presence or ab-
sence of residual diuresis at 6 weeks and 6 months showed 
no significant difference (p = 0.49) between patients with 
or without residual diuresis (Fig. 1c) at 6 weeks. However, 
at 6 months there was a significant difference (p = 0.033; 
Fig. 1d). 
Discussion
The goal of this study was to unravel the association 
between RRF, glucose exposure, and the time to peritoni-
tis. The major finding in our study was that after 6 months 
follow-up the glucose exposure is the most important risk 
factor for the occurrence of peritonitis, independent of 
residual diuresis. This suggests that higher exposure to 
glucose rather than loss of RRF is associated with an in-
creased risk of peritonitis. 
In line with other studies, we confirm in this study that 
use of immunosuppressive drugs as wel as serum albimin 
are both strong significant predictors of PD peritonitis. 
Furthermore, the study showed that at 6 weeks both re-
sidual diuresis as well as daily peritoneal glucose exposure 
did not predict the occurrence of peritonitis. Sensitivity 
analyses with the mean of the urea and CrCl instead of re-
sidual diuresis as measure for RRF yielded similar results. 
Several studies described the protective factor of RRF 
for peritonitis [2, 12, 18]. In our study, we only see after 6 
months of PD that residual diuresis is a protective factor 
for peritonitis. When adjusting for other risk factors, it 
fails to demonstrate a significant role for residual diuresis. 
Obviously, residual diuresis and glucose exposure are 
closely related, because patients with limited residual di-
uresis usually need higher glucose exposure to ensure ad-
equate ultrafiltration. As far as we know, this study is the 
first that included both residual diuresis as peritoneal glu-
cose exposure. This study showed that it is not the resid-
ual diuresis itself, but peritoneal glucose exposure that 
relates to the peritonitis. Several studies have investigated 
the role of peritoneal glucose exposure on developing 
peritonitis. Some studies have found no effect [9, 10], 
whereas other found that glucose exposure was a signifi-
cant factor [11]. These divergent results may be explained 
by differences in the categorization of glucose exposure. 
The studies that found no significant effect of glucose ex-
posure on peritonitis have only investigated this by divid-
ing patients in a high and low glucose group. This ap-
Table 3. Cox regression with univariate and multivariate analysis of baseline and 6 months characteristics and 
the outcome parameter peritonitis
Parameters 6 Weeks
HR (95% CI)
p value 6 Months
HR (95% CI)
p value
Univariate Cox regression analysis
Residual diuresis 0.77 (0.35–1.66) 0.50 0.53 (0.29–0.97) 0.038
Glucose exposure (per 100 g/24 h) 1.99 (0.87–4.56) 0.10 2.93 (1.69–5.08) <0.001
Use of immunosuppressive drugs 3.9 (2.14–7.21) <0.001 – –
Serum albumin, g/L 0.91 (0.85–0.96) 0.001 0.89 (0.82–0.96) 0.004
Multivariate Cox regression analysis
Gender 0.92 (0.46–1.85) 0.82 0.54 (0.26–1.11) 0.09
Age, years 1.00 (0.98–1.01) 0.60 1.00 (0.98–1.02) 0.92
Residual diuresis 1.06 (0.37–3.05) 0.91 0.86 (0.34–2.18) 0.75
Glucose exposure (per 100 g/L) 1.48 (0.58–3.76) 0.41 2.19 (1.11–4.32) 0.02
Immunosuppressive drugs 4.04 (2.13–7.68) <0.001 3.53 (1.66–7.53) 0.001
Albumin, g/L 0.92 (0.87–0.97) 0.004 0.91 (0.83–0.99) 0.02 
Results of univariate and multivariate Cox regression analysis with peritonitis as outcome and listed the vari-
ables as covariate. 
HR, hazard ratio.
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proach might not be sensitive enough to detect the effect 
of glucose exposure on peritonitis. 
Other studies suggest that a high peritoneal glucose 
load increases the risk of peritonitis, perhaps as the effect 
of impaired host defenses, vascular disease, and damage 
to the peritoneal membrane [9–11]. The last years there 
is more knowledge about the influence of glucose expo-
sure on the peritoneum [6, 11, 19, 20]. The human peri-
toneal mesothelial cells play a key role in early peritoneal 
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Fig. 1. a Kaplan-Meier curve showing time to first peritonitis ac-
cording to glucose exposure at 6 weeks. Group 1, the dashed line, 
contains patients with a glucose exposure ≤120 g/24 h (n = 69); 
Group 2, the gray line, contains patients with a glucose exposure 
>120 g/24 h (n = 35). b Kaplan-Meier curve showing time to first 
peritonitis according to glucose exposure at 6 months. Group 1, the 
dashed line, contains patients with a glucose exposure ≤120 g/24 h 
(n = 40); Group 2, the gray line, contains patient with a glucose ex-
posure > 120 g/24 h (n = 51). c Kaplan-Meier analysis of peritonitis-
free survival of the patient groups categorized by the presence or 
absence of residual diuresis at 6 weeks. The gray line represents the 
anuric patients, the dashed line patients with residual diuresis. d 
Kaplan-Meier analysis of peritonitis-free survival of the patient 
groups categorized by the presence or absence of residual diuresis 
at 6 months. The gray line represents the anuric patients, the dashed 





this explains the prevalence of peritonitis. Little is known 
about the glucose concentrations that are necessary to fa-
cilitate bactericidal activity in humans. In vitro studies 
however demonstrate that the bactericidal sugar concen-
trations were much higher than the maximum glucose 
concentrations in the dialysis solutions. In line with this, 
the osmolarity that was bactericidal in vitro was almost 
twice as high as the osmolality of a 3.86% dialysis solution 
[10, 22]. 
Clinical experience learns that the peritoneal mem-
brane characteristics are fully known and developed after 
6 months [23]. Therefore, we are convinced that the pre-
scribed peritoneal glucose dose at 6 months does better 
reflect the true peritoneal characteristics. This is why we 
believe that only at 6 months the glucose exposure pre-
dicts peritonitis. 
The present study has several strengths and weakness-
es. For example, some potential risk factors such as socio-
economic status or personal hygiene were not included. 
Other relevant data representing nutritional status such 
as the subjective global assessment or incidence of culture 
negative peritonitis were also not included. Although ad-
justments for all major risk factors were made, residual 
confounding cannot be excluded due to the observation-
al design of the study. Furthermore, this was a single cen-
ter study.
Major strengths of this study were the inclusion of all 
incident PD patients visiting our center and the relative 
long-term follow-up time. The prospective design in that 
all patients were included directly from start PD and not 
during a random moment during their treatment we be-
lieve to be another strong plus. As already mentioned, this 
study is to our knowledge the first that included both re-
sidual diuresis as peritoneal glucose exposure. 
In conclusion, this study showed that peritoneal glu-
cose exposure and not residual diuresis predicts the oc-
currence of peritonitis. Further studies should shed more 
light to the mechanistical pathways that relate higher 
peritoneal glucose exposure to peritonitis. Future studies 
should further investigate which potential bactericidal 
properties of PD solutions might be clinically relevant. In 
our opinion, this demonstrates the importance of low 
glucose exposure in the prevention of peritonitis. 
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